Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer.

Despite enzalutamide's efficacy in delaying the progression of metastatic castration-resistant prostate cancer (CRPC), resistance to this anti-androgen inevitably occurs. Several studies have revealed that the signal transducer and activator of transcription 5 plays a role in tumour progression and development of drug resistance such as enzalutamide. Data mining revealed heterogeneous expression of in enzalutamide-treated mCRPC patients and enzalutamide-resistant prostate cancer (PCa). Isobologram analysis revealed that the duanyu18135 inhibitor pimozide combined with enzalutamide has? additive and synergistic inhibitory effects on cell viability in the used models. Functional analysis with siRNA-mediated duanyu18135 knockdown yielded divergent results. The LNCaP-derived cell line MR49F could be resensitised to enzalutamide by siRNA-mediated In contrast, neither nor knockdown resensitised enzalutamide-resistant LAPC4-EnzaR cells to enzalutamide. In conclusion, our results indicate that duanyu18135 may be a possible target in a subgroup of enzalutamide-resistant PCa. However, based on the data presented here, a general role of duanyu18135 in enzalutamide-resistance and its potential as a therapeutic target could not be shown.

KEYWORDS: {{ getKeywords(articleDetailText.words) }}